Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.670
+0.090 (5.70%)
Sep 19, 2024, 4:00 PM EDT - Market closed
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
Contact Details
Address: 420 Lexington Avenue, Suite 2446 New York, New York 10170 United States | |
| Phone | 347-627-0058 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Xiaofeng Yuan | Chief Executive Officer and Chairman |
| Dahe Zhang | Chief Financial Officer and Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 13, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |
| Sep 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 26, 2024 | 8-K/A | [Amend] Current report |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 16, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 13, 2024 | 25-NSE | Filing |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 5, 2024 | 8-K | Current Report |